Health Care Bulletin

In 2022, our consultants examined a variety of topics in health care and HEOR, including real-world data and evidence, mergers in the health care industry, and topics presented at our annual Law & Economics Symposium.

These selections highlight a variety of our work in health care and HEOR, including features on the economic burden of depression, health care costs of air pollution, HTA and pharmacoeconomics in Asia, pharmaceutical class actions in the US, and our 2021 Law & Economics Symposium on value through the pharmaceutical product life cycle.

Artificial intelligence algorithms that can lead to better care and coverage. A fresh look at a familiar HEOR metric. An open, rigorous conversation about drug pricing. And a new partnership to advance hematology research in China.

The practice of health care consulting continues to evolve at a rapid pace. The use of real-world evidence (RWE) to complement clinical trial results is expanding, requiring new applications of data science methods and new approaches to determining value. Similarly, breakthroughs in precision medicine call for different ways of predicting long-term value and tailoring payment strategies for innovative therapies.　　　　　　　 　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　

Abuse and misuse of opioids has reached “epidemic” proportions, according to numerous news reports, the US Department of Health and Human Services, the Centers for Disease Control, and the White House. Misuse of prescription opioids, such as oxycodone, hydrocodone, morphine, and methadone, has become a major focus of regulators, manufacturers, prescribers, and researchers.　　　　　　　　　　　　　　　　 　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　

In this issue, we highlight examples of our work and analysis in a number of notable fields in the middle of rapid change. Analysis Group experts from the Health Care practice offer insights into developing trends in health care economics and outcomes research and litigation, including biosimilars introduction, the use of machine learning in health care litigation, regulatory approval processes and guidelines, and the economic costs of schizophrenia and obesity.

From the rising impact of diseases such as depression and obesity to the rapid expansion of medical data, many of the challenges facing global health care systems represent new aspects of foundational issues. In this Bulletin, leaders of Analysis Group’s Health Care practice draw on their experience and research to offer insights to improve decision making and outcomes.